BioRestorative Therapies, Inc. (NASDAQ: BRTX) received a Notice of Allowance from the Japanese Patent Office for its ThermoStem® platform, covering the company’s all‑off‑the‑shelf brown adipose‑derived stem cell (BADSC) technology and a suite of encapsulation and delivery methods, including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolding systems.
The allowance expands protection for ThermoStem’s potential cell‑based alternatives to GLP‑1 drugs, a rapidly growing therapeutic category in the obesity and metabolic disorder market. The company’s CEO, Lance Alstodt, said the patent “validates the significant progress we have made with ThermoStem” and that the new protection “advances BioRestorative into a highly attractive commercial position as we continue discussions with potential strategic partners.” The $100 billion obesity market referenced in the announcement is a projection for the end of the decade, not the current market size.
While the patent milestone is significant, BioRestorative’s financial statements show ongoing challenges: the company reported negative operating margins and a low Altman Z‑Score, indicating financial distress. The company’s press releases also contain a cautionary statement that “no assurances can be given that a license or partnership agreement will be entered into with such company whether on commercially reasonable terms or otherwise.”
BioRestorative has also secured other international patent allowances for ThermoStem, including an Israeli allowance in October 2024, which was the 14th international patent outside the U.S. for the platform. The company’s broader focus includes its Disc/Spine Program (BRTX‑100) and a BioCosmeceutical platform, and it recently announced a new commercial leadership team and a registered direct offering in early October 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.